United Therapeutics Corporation (UTHR)
Profitability ratios
Return on sales
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit margin | 89.24% | 88.94% | 88.85% | 88.87% | 88.94% | 89.00% | 90.08% | 91.16% | 92.32% | 93.15% | 93.41% | 92.91% | 92.73% | 92.59% | 92.52% | 92.85% | 92.71% | 92.76% | 92.24% | 92.24% |
| Operating profit margin | 47.86% | 46.42% | 48.28% | 50.31% | 50.91% | 49.92% | 51.53% | 46.99% | 48.27% | 49.94% | 47.15% | 51.39% | 32.98% | 27.27% | 27.90% | 24.04% | 40.02% | 41.99% | 38.72% | 44.02% |
| Pretax margin | 53.49% | 52.17% | 53.54% | 55.28% | 54.75% | 52.52% | 52.98% | 47.13% | 49.09% | 49.05% | 44.96% | 49.21% | 35.24% | 34.30% | 36.62% | 33.19% | 43.07% | 42.06% | 37.79% | 45.56% |
| Net profit margin | 41.53% | 40.31% | 40.87% | 42.05% | 42.31% | 40.82% | 41.29% | 36.76% | 37.56% | 38.03% | 35.27% | 38.87% | 28.23% | 27.94% | 29.61% | 26.92% | 34.71% | 33.25% | 30.04% | 36.59% |
The profitability ratios of United Therapeutics Corporation have shown some fluctuations over the past few years.
1. Gross Profit Margin: The company's gross profit margin has generally ranged from 88% to 93%, indicating that the company is efficient in managing its production costs and generating profits from its core business activities.
2. Operating Profit Margin: The operating profit margin has fluctuated between 24% and 51%, reflecting variability in the company's ability to control its operating expenses and generate profits from its primary operations.
3. Pretax Margin: The pretax margin has shown a wider range between 33% and 55%, suggesting fluctuations in the company's ability to manage its overall expenses and generate profits before tax obligations.
4. Net Profit Margin: The net profit margin has ranged from 26% to 42%, reflecting the company's ability to maintain profitability after all expenses, including taxes, have been accounted for.
Overall, United Therapeutics Corporation has maintained healthy profitability margins, although some fluctuations indicate the need for careful monitoring of operational efficiencies and cost management strategies to sustain profitability in the long term.
Return on investment
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | 18.70% | 17.96% | 18.79% | 19.35% | 16.53% | 15.67% | 16.28% | 14.67% | 15.46% | 16.07% | 15.21% | 16.95% | 10.75% | 8.94% | 9.16% | 7.80% | 12.86% | 13.42% | 13.13% | 15.77% |
| Return on assets (ROA) | 16.23% | 15.60% | 15.91% | 16.17% | 13.74% | 12.81% | 13.04% | 11.48% | 12.03% | 12.24% | 11.38% | 12.83% | 9.20% | 9.16% | 9.72% | 8.74% | 11.15% | 10.62% | 10.19% | 13.11% |
| Return on total capital | 23.82% | 23.62% | 24.51% | 26.72% | 22.28% | 21.25% | 22.07% | 19.79% | 21.32% | 21.41% | 19.99% | 22.27% | 16.47% | 16.34% | 17.69% | 16.25% | 20.86% | 20.32% | 20.02% | 25.11% |
| Return on equity (ROE) | 18.55% | 18.21% | 18.77% | 19.68% | 16.46% | 15.75% | 16.11% | 14.22% | 15.16% | 15.51% | 14.61% | 16.46% | 12.02% | 12.07% | 12.94% | 11.77% | 15.16% | 14.27% | 13.89% | 17.90% |
United Therapeutics Corporation has shown a positive trend in its profitability ratios over the analyzed periods.
- Operating return on assets (Operating ROA) has increased steadily from 15.77% as of March 31, 2020, to 18.70% as of December 31, 2024, with some fluctuations in between.
- Return on assets (ROA) has also experienced growth, with an upward trajectory from 13.11% on March 31, 2020, to 16.23% on December 31, 2024, showing improvement in the company's ability to generate profits from its total assets.
- Return on total capital has shown a similar positive trend, increasing from 25.11% as of March 31, 2020, to 23.82% as of December 31, 2024, indicating efficient utilization of both equity and debt capital to generate returns for the company.
- Return on equity (ROE) has also demonstrated improvement, rising from 17.90% on March 31, 2020, to 18.55% on December 31, 2024, revealing efficient returns to the company's shareholders over the analysis period.
In conclusion, United Therapeutics Corporation has exhibited a consistent improvement in its profitability ratios, indicating effective management of assets, capital, and equity to generate returns for both the company and its shareholders.